The head of an Israeli study into the efficacy of the fourth vaccine against Covid-19 calls the observed fivefold increase in the number of antibodies “good, but not enough”.
“We see a certain increase in antibodies, but that increase is not very impressive,” said Professor Gili Regev on Wednesday.
Shortly after the fourth shot, people return to the level of antibodies from shortly after the third, Regev said, but she said she had “expected more” from a second booster shot. “The goal cannot be to be vaccinated against the coronavirus every four months,” it sounds.
Regev said she was pleased that vulnerable groups, such as people with weakened immune systems and over 60 in Israel, are already receiving the fourth dose. “But I’m really not sure if it should be given to everyone now. We need more information.”
At the same time, the professor emphasized the enormous importance of the first booster vaccination. “Whoever received the first and second dose should urgently receive the third.” She said that those who have not yet received a booster should “run” to the vaccination centre.
Another trial of a fourth dose started on Wednesday at Sheba Hospital in Tel Aviv. 150 participants will receive a fourth vaccination with Moderna after three doses of Pfizer/BioNTech.
Only about 61 percent of the 9.4 million Israelis are still considered fully vaccinated. These are people up to six months after the second dose and people who have already received the first booster. About 30 percent of the population is not vaccinated at all, and 9 percent has expired.
More than four million Israelis have already received their third vaccination dose, and more than 70,000 their fourth, according to the Ministry of Health.